Lawmakers led by Rep. Greg Murphy, MD, R-N.C., are reintroducing the Provider Reimbursement Stability Act of 2026, which is endorsed by the AMA and MGMA.
U.K.-based Lucida Medical’s diagnostic tool is already deployed by the NHS, with the company earmarking the funds for the pursuit of regulatory approval in the U.S.
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
New findings from a large CT lung cancer screening dataset reveal that a substantial number of patients have significant incidental findings visible on their scans.
Society of Nuclear Medicine and Molecular Imaging President, Cathy Cutler, explains the long road to jump-starting a new U.S. domestic supply of imaging isotopes.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
More than 100 plaintiffs have now sued the Marlborough, Massachusetts-based mammography-maker, claiming they suffered injuries and emotional distress stemming from implantation of the BioZorb radiographic marker.
“With this signal about the public’s preference for notification, the question for health systems and policymakers is not whether to notify patients but when and how.”
Lawmakers led by Rep. Greg Murphy, MD, R-N.C., are reintroducing the Provider Reimbursement Stability Act of 2026, which is endorsed by the AMA and MGMA.
